Description

SUSTANON 250 is a multi-ester injectable formulation of testosterone commonly employed in androgen replacement therapy for males presenting with primary or secondary hypogonadism. It is indicated in individuals with delayed onset of puberty, impaired testicular function, or those who have experienced gonadal suppression due to cytotoxic treatments such as chemotherapy. The preparation delivers a sustained release of testosterone through a combination of four distinct esters, optimizing both the onset and duration of action. Each 1ml ampoule contains 60mg of testosterone phenylpropionate, 60mg of testosterone isocaproate, 100mg of testosterone decanoate, and 30mg of testosterone propionate, dissolved in an oil-based excipient matrix.

Metabolic Interactions

Testosterone exerts its physiological effects via intracellular androgen receptor binding, initiating a cascade of gene expression that supports both androgenic and anabolic pathways. It plays an integral role in spermatogenesis, development of male secondary sexual features, and regulation of libido. The compound also influences estrogenic pathways through peripheral aromatization. Its anabolic activity promotes nitrogen retention, skeletal muscle hypertrophy, enhanced erythropoiesis, and increases in bone mineral density and maturation.

Dosage

Standard intramuscular administration is recommended once every 3 to 4 weeks, depending on individual clinical response and serum testosterone levels.

Drug Interactions

Prior to initiating therapy with SUSTANON 250, patients should inform their healthcare provider if they are concurrently using any of the following agents:

• Antidiabetic medications (may alter glycemic control)
• Warfarin (potentiation of anticoagulant effect)
• Propranolol (altered metabolism)
• Corticosteroids (risk of fluid retention)
• Oxyphenbutazone (pharmacokinetic interactions)